Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China

Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China

Abstract Background Pegylated interferon (PEG-IFN) alfa-2b is recommended for chronic hepatitis B (CHB). We aimed to investigate the sustainability of off-treatment responses among Chinese HBeAg-positive CHB patients treated with PEG-IFN alfa-2b from a randomized trial. Methods Eligible Chinese pati...

Full description

Bibliographic Details
Main Authors: Jian Sun, Huiguo Ding, Guofeng Chen, Guiqiang Wang, Lai Wei, Jiming Zhang, Qing Xie, Mobin Wan, Hong Tang, Shijun Chen, Zhiliang Gao, Yuming Wang, Dazhi Zhang, Wenxiang Huang, Jifang Sheng, Qin Ning, Dongliang Yang, Jian Lu, Chen Pan, Yuxiu Yang, Jue Wang, Chuanzhen Sun, Qixin Wang, Jinlin Hou
Format: Article
Language:English
Published: BMC 2019-05-01
Series:BMC Gastroenterology
Subjects:
Chronic hepatitis B
Peg-interferon
Long-term follow-up
Sustained serological response
Sustained combined clinical response
Online Access:http://link.springer.com/article/10.1186/s12876-019-0981-5

Internet

http://link.springer.com/article/10.1186/s12876-019-0981-5

Similar Items